· ONCOS-102 combined with chemotherapy demonstrated 34.1% overall survival (OS)
rate at 30 months in first line patients, compared to 0% in the chemotherapy
-only group
  · ONCOS-102 promoted robust immune responses, including an association between
T-cell infiltration and patient survival

Oslo, Norway, 4 September 2023- Circio Holding ASA (OSE: CRNA), a biotechnology
company developing novel circular RNA and immunotherapy medicines, today
announces that the completed phase 1/2 trial of ONCOS-102 in combination with
Standard of Care (SoC) chemotherapy in malignant pleural mesothelioma (MPM) has
been published in the Journal for ImmunoTherapy of Cancer (JITC), the
prestigious immunology journal of the Society for Immunotherapy of Cancer
(SITC).

The study was a randomized phase 1/2 trial adding ONCOS-102 to SoC chemotherapy
(pemetrexed/cisplatin) in first and later line MPM to assess safety, immune
activation and clinical efficacy in a total of 31 patients. The ONCOS-102 and
SoC combination showed a favorable safety profile, robust immune responses in
injected tumors and a signal of clinical benefit. In first line patients, the OS
rate at 30 months was 34.1% for ONCOS-102-treated patients, which is a clear
improvement over the first-line SoC-only control group where the OS rate was 0%.

Title of publication: ONCOS-102 plus pemetrexed and platinum chemotherapy in
malignant pleural mesothelioma: a randomized phase 2 study investigating
clinical outcomes and the tumor microenvironment

For the full publication, please see link:
https://jitc.bmj.com/content/11/9/e007552

Margrethe Sørgaard, VP and Head of Clinical at Circio, said: "Mesothelioma
remains a challenging disease with poor prognosis and few available treatment
options. In this exploratory trial, ONCOS-102 demonstrated a clear signal of
clinical benefit for this underserved patient group, particularly in an early
treatment setting. Importantly, the study also showed that ONCOS-102 can be
safely and effectively combined with chemotherapy and drive robust immune
activation in an immunologically cold tumor type, thereby demonstrating the
versatility of the product and expanding future development opportunities."

***

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com (erik.wiklund@targovax.com)

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@circio.com (renate.birkeli@targovax.com)

About Circio

Building next generation RNA therapeutics

Circio Holding ASA is a biotechnology company developing novel circular RNA and
immunotherapy medicines.

Circio has established a unique circular RNA (circRNA) platform to develop novel
circRNA medicines for cancer, vaccines, rare disease, protein replacement
therapy and cell therapy. The proprietary circVec technology is based on a
modular genetic cassette design for efficient biogenesis of multifunctional
circRNA that can be deployed for many purposes. The most advanced concept,
circAde, builds on the companyŽs validated adenovirus platform to deliver
circRNA for durable expression of therapeutic proteins directly into cancer
cells. This unique approach is the only currently known circRNA program capable
of targeting solid tumors. The circVec platform has broad potential
applications, and CircioŽs strategy is to generate one or more lead candidates
for in house development in specific disease indications and in parallel seek
partnerships for other technical applications and therapeutic areas. The circRNA
R&D activities are being conducted by the wholly owned subsidiary Circio AB
based at the Karolinska Institute in Stockholm, Sweden.

In addition to Circio's circRNA program, the Company's' clinical stage
immunotherapy programs are designed to activate the patientŽs own immune system
to fight cancer cells and provide benefit to patients with no or few treatment
alternatives. ONCOS-102 has demonstrated an excellent safety profile, strong
immune responses and clinical efficacy in several cancer types in Phase 1/2
studies, both as monotherapy and in combinations with checkpoint inhibitors or
standard-of-care chemotherapy. A phase 2 trial to confirm the therapeutic
activity of ONCOS-102 in melanoma patients resistant to PD-1 checkpoint
inhibitor treatment has been designed, and Circio is seeking external financing
and/or partnerships to continue the clinical development.

Circio's second clinical stage program is an immunotherapy targeting KRAS driver
mutations. TG01 has previously shown robust immune responses and encouraging
clinical benefit in surgically resected pancreatic cancer and is currently being
tested in two clinical trials in RAS-mutated pancreatic cancer and multiple
myeloma in the USA and Norway. These studies are being run through academic
collaborative networks, supported by prestigious research grants from Innovation
Norway and the Norwegian Research Council, creating broad future optionality for
the TG01 program at low cost to Circio.